Medications known as GLP-1 receptor agonists, widely used to manage Type 2 diabetes and support weight loss, are now being linked to a modest increase in the risk of erectile dysfunction (ED), according to a recent 2026 study using a target trial emulation design published in the Journal eClinicalMedicine
The response has been remarkable
de Paiva CS
Across both programs, researchers tracked adverse events meticulously, documenting everything from nausea to injection site reactions
What the Head-to-Head Evidence Shows for Blood Glucose The most direct comparison of oral semaglutide against an injectable GLP-1 receptor agonist is PIONEER 4, a randomized, double-blind, double-dummy phase 3a trial in 711 adults with type 2 diabetes on stable metformin, with or without an SGLT2 inhibitor, across 100 sites in 12 countries
Zhao T, Yu LH, Zhang HL, Yu J, Feng J, Wang TT, et al